Fiche personne
Directeur scientifique du Cancéropôle Est
Territoire
Bourgogne
Statut
Coordinateur
Affiliation
Publications
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, Hennequin A, Ladoire S, Rederstorff E, Fumoleau P, Isambert N, Bonnin N, You B, Freyer G, Desmoulins I, Schmitt A
Cancer Chemother Pharmacol. 2022 Jan 8;:
[Adapting to the SARS-CoV2 pandemic: Experience of the Curie Institute].
Lucchi-Angellier E, Mino JC, Burnod A, Cottu P, Bozec L, Escalup L, Massing L, Papon M, Rizand P, Fumoleau P, Bouleuc C
Bull Cancer. 2021 09;108(9):787-797
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM,
Lancet. 2019 Jun 6;:
Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions.
Mamguem Kamga A, Dumas A, Joly F, Billa O, Simon J, Poillot ML, Darut-Jouve A, Coutant C, Fumoleau P, Arveux P, Dabakuyo-Yonli TS
Oncologist. 2018 Dec 21;:
Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
Jacquinot Q, Paget-Bailly S, Fumoleau P, Romieu G, Pierga JY, Espié M, Lortholary A, Nabholtz JM, Mercier CF, Pauporté I, Henriques J, Pivot X
Breast. 2018 Jun 15;41:1-7
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H
BMC Cancer. 2018 05 4;18(1):526
Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.
Humbert O, Lasserre M, Bertaut A, Fumoleau P, Coutant C, Brunotte F, Cochet A
J. Nucl. Med.. 2018 Feb 9;:
FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A
PLoS ONE. 2018 ;13(7):e0199529
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.
Bellaye PS, Oudot A, Vrigneaud JM, Raguin O, Bichat F, Vaslin A, Maby-El Hajjami H, Zanna C, Vuagniaux G, Fumoleau P, Denat F, Brunotte F, Collin B
Contrast Media Mol Imaging. 2018 ;2018:8494031
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG
Breast Cancer Res.. 2017 Aug;19(1):98
Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer.
Gonssaud B, Goussot V, Berriolo-Riedinger A, Saïtta-Aribau E, Coutant C, Cochet A, Fumoleau P, Riedinger JM
Ann. Biol. Clin. (Paris). 2017 Aug;75(4):421-429
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
Pivot X, Fumoleau P, Pierga JY, Delaloge S, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulié P, Jacquin JP, Lavau-Denes S, Kerbrat P, Cox D, Faure-Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G
Eur. J. Cancer. 2017 Jun;81:151-160
Exosomes in cancer theranostic: Diamonds in the rough.
Cordonnier M, Chanteloup G, Isambert N, Seigneuric R, Fumoleau P, Garrido C, Gobbo J
Cell Adh Migr. 2017 Mar;11(2):151-163
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].
Ladoire S, Derangère V, Arnould L, Thibaudin M, Coudert B, Lorgis V, Desmoulins I, Chaix M, Fumoleau P, Ghiringhelli F
Ann Pathol. 2017 Feb;37(1):133-141
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG
NPJ Breast Cancer. 2017 ;3:4
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F
Breast Cancer Res. Treat.. 2017 Jan;161(1):73-81
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L
Oncotarget. 2017 Jan;8(2):1957-1971
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O, Riedinger JM, Vrigneaud JM, Kanoun S, Dygai-Cochet I, Berriolo-Riedinger A, Toubeau M, Depardon E, Lassere M, Tisserand S, Fumoleau P, Brunotte F, Cochet A
J. Nucl. Med.. 2016 Nov;57(11):1707-1712
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X
Oncotarget. 2016 Nov;7(47):77358-77364
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G
Nat Commun. 2016 Jul;7:12222
[CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
Riedinger JM, Goussot V, Desmoulins I, Lorgis V, Coutant C, Beltjens F, Lizard S, Fumoleau P
Bull Cancer. 2016 May;103(5):434-43
Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.
Gobbo J, Marcion G, Cordonnier M, Dias AM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clausse V, Rébé C, Bertaut A, Goussot V, Lirussi F, Ghiringhelli F, de Thonel A, Fumoleau P, Seigneuric R, Garrido C
J. Natl. Cancer Inst.. 2016 Mar;108(3):
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.
Diéras V, Bachelot T, Campone M, Isambert N, Joly F, Le Tourneau C, Cassier P, Bompas E, Fumoleau P, Noal S, Orsini C, Jimenez M, Imbs DC, Chatelut E
Oncol Ther. 2016 ;4(2):211-223
Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X, Aulagner G, Blay JY, Fumoleau P, Kaliski A, Sarkozy F, Limat S
Anticancer Drugs. 2015 Nov;26(10):1009-16
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.
Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G
Autophagy. 2015 Oct 3;11(10):1878-90
HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, Coudert B, Fumoleau P, Arveux P, Arnould L
Eur J Cancer Care (Engl). 2015 Oct 27
[Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer].
Konan S, Goussot V, Desmoulins I, Lorgis V, Coutant C, Fumoleau P, Beltjens F, Dalban C, Lizard S, Riedinger JM
Bull Cancer. 2015 Oct;102(10):834-44
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roche H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M
Future Oncol. 2015 Aug;11(16):2283-97
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P
Eur J Cancer. 2015 Jul 7. pii: S0959-8049(15)00499-2
Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer.
Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F
Clin Cancer Res. 2015 Jun 30. pii: clincanres.0384.2015.
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.
Schmitt E, Vegran F, Chevrier S, Burillier L, Cadouot M, Lizard-Nacol S, Coudert B, Fumoleau P, Arnould L, Boidot R
BMC Cancer. 2015 Mar 24;15(1):169.
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer - results of a first-in-man dose escalation study with a fixed dose extension phase.
Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P
Ann Oncol. 2015 Feb 2. pii: mdv031.
Role of positron emission tomography for the monitoring of response to therapy in breast cancer.
Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P
Oncologist. 2015 Feb;20(2):94-104
Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R
Int J Oncol. 2014 Sep;45(3):1167-74
Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.
Degrolard-Courcet E, Sokolowska J, Padeano MM, Guiu S, Bronner M, Chery C, Coron F, Lepage C, Chapusot C, Loustalot C, Jouve JL, Hatem C, Ferrant E, Martin L, Coutant C, Baurand A, Couillault G, Delignette A, El Chehadeh S, Lizard S, Arnould L, Fumoleau P, Callier P, Mugneret F, Philippe C, Frebourg T, Jonveaux P, Faivre L
Eur J Hum Genet. 2014 Aug;22(8):979-87
HER2-positive breast cancer: (1)(8)F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F
Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.
Kramar A, Bachelot T, Madrange N, Pierga JY, Kerbrat P, Espie M, Fumoleau P, Pauporte I, Khayat D, Romieu G, Pivot X
Ann Oncol. 2014 Aug;25(8):1563-70
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H, Litiere S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmstrom P, Werutsky G, Bogaerts J, Bergh J, Cameron DA
Ann Oncol. 2014 Jun;25(6):1128-36
(1)(8)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, Fumoleau P, Brunotte F
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27
Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.
Ladoire S, Dalban C, Roche H, Spielmann M, Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F, Ghiringhelli F
Eur J Cancer. 2014 Feb;50(3):506-16
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.
Dabakuyo TS, Arnaud A, Maingon P, Causeret S, Coudert B, Fumoleau P, Arnould L, Poillot ML, Arveux P, Crehange G, Bonnetain F
Eur J Cancer Care (Engl). 2013 Sep;22(5):638-47
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espie M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A
Lancet Oncol. 2013 Jul;14(8):741-8
Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.
Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, Crehange G, Coutant C, Fumoleau P, Coudert B
Breast. 2013 Jun;22(3):301-8
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
Fumoleau P, Trigo JM, Isambert N, Semiond D, Gupta S, Campone M
BMC Cancer. 2013 Oct 7;13:460
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.
Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M
BMC Cancer. 2013 Apr 2;13:172
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.
Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F
Ann Oncol. 2012 Oct;23(10):2572-7
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Ladoire S, Mignot G, Dalban C, Chevriaux A, Arnould L, Rebe C, Apetoh L, Boidot R, Penault-Llorca F, Fumoleau P, Roche H, Spielmann M, Levy C, Lortholary A, Eichler F, Mesleard C, Bonnetain F, Ghiringhelli F
Ann Oncol. 2012 Oct;23(10):2552-61
Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.
Le Ray I, Dabakuyo S, Crehange G, Bardou M, Arnould L, Fraisse J, Fumoleau P, Coudert B, Causeret S, Arveux P, Maingon P, Bonnetain F
Eur J Cancer. 2012 Oct;48(15):2300-10
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
Freyer G, Isambert N, You B, Zanetta S, Falandry C, Favier L, Trillet-Lenoir V, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Fumoleau P
Br J Cancer. 2012 Aug 7;107(4):598-603
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J
J Clin Oncol. 2012 May 10;30(14):1594-600
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M, Isambert N, Bourbouloux E, Roche H, Bonneterre J, Milano G, Fumoleau P
Cancer Chemother Pharmacol. 2012 Apr;69(4):871-9
Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F
J Nucl Med. 2012 Apr;53(4):512-20
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
Isambert N, Freyer G, Zanetta S, You B, Fumoleau P, Falandry C, Favier L, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Trillet-Lenoir V
Clin Cancer Res. 2012 Mar 15;18(6):1743-50
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
Brain E, Isambert N, Dalenc F, Dieras V, Bonneterre J, Rezai K, Jimenez M, Mefti-Lacheraf F, Cottura E, Tresca P, Vanlemmens L, Mahier-Ait Oukhatar C, Lokiec F, Fumoleau P
Br J Cancer. 2012 Feb 14;106(4):673-7
Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F
Breast Cancer Res Treat. 2011 Dec;130(3):845-54
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.
Brain E, Levy C, Serin D, Roche H, Spielmann M, Delva R, Veyret C, Mauriac L, Rios M, Martin AL, Jimenez M, Asselain B, Gauthier M, Bonnetain F, Fumoleau P
Br J Cancer. 2011 Nov 8;105(10):1480-6
Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
Ladoire S, Rambach L, Quipourt V, Favier L, Ghiringhelli F, Arnould L, Pfitzenmeyer P, Fumoleau P, Coudert B
Clin Breast Cancer. 2011 Aug;11(4):235-40
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F
J Pathol. 2011 Jul;224(3):389-400
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
Ladoire S, Arnould L, Mignot G, Apetoh L, Rebe C, Martin F, Fumoleau P, Coudert B, Ghiringhelli F
Br J Cancer. 2011 Jul 26;105(3):366-71
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, Andre S, Litiere S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R
Lancet Oncol. 2011 Jun;12(6):527-39
Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F
Breast Cancer Res Treat. 2011 Jan;125(1):65-72
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.
Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, Tixier H, Guiu B, Penault-Llorca F, Ettore F, Fumoleau P, Arnould L
Br J Cancer. 2010 Oct 26;103(9):1335-42.
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, Loadman P, Capizzi R, Grieshaber C, Fumoleau P
Eur J Cancer. 2010 Mar;46(4):729-34
[Management of metastatic HER2-positive breast cancer: present and future]
Guiu S, Coudert B, Favier L, Arnould L, Fumoleau P
Bull Cancer. 2010 Mar;97(3):365-83.
2009 Report on the state of knowledge of tissular biomarkers uPA-PAI-1, Oncotype DX (TM) and Mammaprint (R) in breast cancer care
Luporsi E, Andre F, Bellocq JP, Caron Y, Fumoleau P, Gompel A, Martin PM, Roche H, Salmon R, Sigal-Zafrani B, Spyratos F, Kassab-Chahmi D, Bosquet L, Mazeau-Woynar V
Oncologie. 2010 Feb;12(2):158-63
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhomme C
Gynecol Oncol. 2010 Feb;116(2):157-62.
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
Vegran F, Boidot R, Coudert B, Fumoleau P, Arnould L, Garnier J, Causeret S, Fraise J, Dembele D, Lizard-Nacol S
Br J Cancer. 2009 Oct 20;101(8):1357-64
Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
Arnould L, Coudert B, Fumoleau P
J Clin Oncol. 2009 Jun 1;27(16):2733; author reply 2734-5
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S
Cancer Invest. 2009 Jun;27(5):521-8.
Interest in association of bevacizumab/irinotecan in the treatment of glioblastoma. A multicentric study of ANOCEF
Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Xuan KH, Chauffert B
Rev Neurol. 2009 Jan;165 Suppl. 1:S16-8
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ
J Clin Oncol. 2008 Oct 1;26(28):4659-65.
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]
Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B
Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F
Clin Cancer Res. 2008 Apr 15;14(8):2413-20.
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Favier L, Isambert N, Zanetta S, Ferrant E, Mayer F, Chauffert B, Fumoleau P, Garnier J, Biville F, Coudert B
Breast. 2008 Feb;17(1):36-41
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1915-24
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP
Clin Cancer Res. 2007 Nov 1;13(21):6404-9.
Angiogenesis targeting in breast cancer
Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E
Bull Cancer. 2007;94(7 Suppl):F199-206.
Targeting ErbB receptors in breast cancer
Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E
Bull Cancer. 2007;94(7 Suppl):F147-70.
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
Fumoleau P, Coudert B, Isambert N, Ferrant E
Ann Oncol. 2007 Jul;18 Suppl 5:v9-15.
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
Campone M, Isambert N, Bourbouloux E, Maury S, Monin-Baroille P, Berille J, Fumoleau P
Cancer Chemother Pharmacol. 2007 Apr;59(5):689-95
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B
Anticancer Drugs. 2006 Nov;17(10):1211-7.
Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.
Hery M, Bonneterre J, Roche H, Luporsi E, Kerbrat P, Namer M, Fumoleau P, Monnier A, Fargeot P
Bull Cancer. 2006 Oct 1;93(10):E109-14.
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Campone M, Fumoleau P, Viens P, Dieras V, Pujade-Lauraine E, Serin D, Petit T, Espie M, Kayitalire L, Bozec L, Pouillart P
Breast. 2006 Oct;15(5):601-9.
[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]
Grangeasse L, Coudert B, Pivot X, Fumoleau P, Depierre A, Chauffert B, Huichard S, Woronoff-Lemsi MC, Arveux P, Limat S
Bull Cancer. 2006 Oct 1;93(10):1047-54.
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Molucon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P
Ann Oncol. 2006 Mar;17(3):409-14
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E
Ann Oncol. 2006 Jan;17(1):85-92
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].
Campone M, Merlin JL, Fumoleau P
Bull Cancer. 2003 Jul;90(7):614-22
